Travere Therapeutics to Host Virtual R&D Day on Wednesday, December 9, 2020
Travere Therapeutics will host a virtual R&D Day on December 9, 2020, at 12:00 p.m. ET, to discuss key pipeline programs.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Travere Therapeutics will host a virtual R&D Day on December 9, 2020, at 12:00 p.m. ET, to discuss key pipeline programs. The event will feature presentations from external experts and Travere’s senior management team, including Eric Dube, CEO, and Noah Rosenberg, CMO. Interested participants can access the live webcast on Travere's website in the 'Events & Presentations' section. A replay will be available for up to 60 days.
Travere is committed to developing therapies for patients with rare diseases.
Details
News Market Reaction – TVTX
The recorded move for TVTX in the trading session of this news was +0.78%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced that the Company will host a virtual R&D Day on Wednesday, December 9, 2020 at 12:00 p.m. ET to review the Company’s key pipeline programs. The event will feature presentations from external experts and the Travere Therapeutics senior management team.
Presenters:
- Jonathan Hogan, M.D., assistant professor of medicine at the Perelman School of Medicine, University of Pennsylvania, & clinical director, Penn Glomerular Center
- Jonathan Barratt, Ph.D., FRCP, Mayer professor of renal medicine at the University of Leicester & John Walls Renal Unit, Leicester
- Eric Dube, Ph.D., chief executive officer at Travere Therapeutics
- Noah Rosenberg, M.D., chief medical officer at Travere Therapeutics
- William Rote, Ph.D., senior vice president of research and development at Travere Therapeutics
- Peter Heerma, chief commercial officer at Travere Therapeutics
Virtual R&D Day Information:
- Date: Wednesday, December 9, 2020
- Time: 12:00 p.m. ET (9:00 a.m. PT)
- Live webcast: Travere.com in the “Events & Presentations” section of the “Investors and Media” Page
A replay of the webcast will be available at https://ir.travere.com/events-presentations and will be accessible for up to 60 days.
About Travere Therapeutics
At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@travere.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.